Metsera (NASDAQ:MTSR - Get Free Report) issued its earnings results on Wednesday. The company reported ($3.52) EPS for the quarter, Zacks reports.
Metsera Stock Performance
Shares of NASDAQ MTSR traded down $2.01 during midday trading on Friday, reaching $28.00. 627,537 shares of the company traded hands, compared to its average volume of 667,450. Metsera has a 52 week low of $23.08 and a 52 week high of $32.81.
Analysts Set New Price Targets
A number of research firms have issued reports on MTSR. Guggenheim assumed coverage on Metsera in a research note on Tuesday, February 25th. They issued a "buy" rating and a $56.00 target price on the stock. Bank of America initiated coverage on shares of Metsera in a research note on Tuesday, February 25th. They set a "buy" rating and a $38.00 target price for the company. Evercore ISI began coverage on shares of Metsera in a research note on Tuesday, February 25th. They issued an "outperform" rating on the stock. Finally, Cantor Fitzgerald began coverage on Metsera in a report on Tuesday, February 25th. They set an "overweight" rating on the stock.
Get Our Latest Analysis on MTSR
Metsera Company Profile
(
Get Free Report)
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Read More
Before you consider Metsera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Metsera wasn't on the list.
While Metsera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
